^
    Back
    Association details:
    Biomarker:EGFR L858R + ALK rearrangement
    Cancer:Lung Adenocarcinoma
    Drug:Gilotrif (afatinib) (pan-HER inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Porto Biomed J
    Title:

    Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review

    Published date:
    02/11/2021
    Excerpt:
    We describe a case of a woman with stage IV lung adenocarcinoma with 2 synchronous mutations at diagnosis, the EGFR p.(Leu858Arg) mutation, and an ALK rearrangement….She started treatment with gefitinib 250 mg in February/2019. After 16 months, she maintains gefitinib with stable disease...
    DOI:
    10.1097/j.pbj.0000000000000124